



Figure S1: Anti-proliferative effects of rhMG53 on parental KB-3-1 and ABCB1-overexpressing KB-C2 cells. Cytotoxicity assay (MTT assay) was performed to evaluate the anti-proliferative effects of rhMG53 on parental and ABCB1-overexpressing cells. The data are representation of mean \pm SD for three independent experiments performed in triplicates.

Table S1.

The effect of rhMG53 on reversal of ABCB1-mediated MDR

Treatment	IC ₅₀ \pm SD ^a (μM) (RF ^b)	
	KB-3-1	KB-C2
Doxorubicin	0.14 \pm 0.01 (1.00)	7.20 \pm 0.31 (51.47)
+ 0.3 μM rhMG53	0.12 \pm 0.01 (0.84)	7.19 \pm 0.26 (51.37)
+ 1 μM rhMG53	0.11 \pm 0.01 (0.78)	6.56 \pm 0.98 (46.85)
+ 3 μM rhMG53	0.11 \pm 0.03 (0.80)	4.94 \pm 1.06 (35.26)
+ 3 μM Verapamil	0.17 \pm 0.01 (1.21)	0.56 \pm 0.01 (3.97) ^c

^a IC₅₀ is presented as mean \pm SD value of three independent experiments (n=3) each performed in triplicates

^b RF: Resistance fold is the IC₅₀ value of substrate drug with or without inhibitor over the IC₅₀ of substrate drug in parental cells without inhibitor

^c P < 0.05 compared to the control group in the absence of reversal agent